更新于：2024-05-01
Nifedipine
硝苯地平
更新于：2024-05-01
概要
基本信息
简介硝苯地平是一种小分子药物，可作为电压依赖性钙通道 (VDCC) 的阻断剂，VDCC 参与心血管系统中钙离子的调节。 通过抑制这些通道，硝苯地平减少钙流入平滑肌细胞，导致血管扩张和血压下降。 该药主要用于治疗高血压，包括肾血管性和原发性高血压，以及心绞痛和其他心血管疾病。 硝苯地平最初由拜耳公司开发和销售，并于 1975 年获得首次批准。从那时起，它已成为一种广泛用于治疗高血压和相关疾病的药物，尽管它的使用与潜在的副作用有关，如低血压、 头晕和头痛。 因此，应谨慎使用并在医疗保健专业人员的监督下使用。 |
药物类型 小分子化药 |
别名 Nifedine、Nifedipine (JP17/USP/INN)、Nifedipine OSAT + [37] |
靶点 |
作用机制 Cav2.1抑制剂(calcium voltage-gated channel subunit alpha1 A inhibitors) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 德国 (1975-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C17H18N2O6 |
InChIKeyHYIMSNHJOBLJNT-UHFFFAOYSA-N |
CAS号21829-25-4 |
关联
274
项与 硝苯地平 相关的临床试验Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)
100 项与 硝苯地平 相关的临床结果
登录后查看更多信息
100 项与 硝苯地平 相关的转化医学
登录后查看更多信息
100 项与 硝苯地平 相关的专利（医药）
登录后查看更多信息
19,434
项与 硝苯地平 相关的文献（医药）2024-03-01Fertility and sterility
Penile vibratory stimulation in men with spinal cord injury: an educational video demonstration.
Article
作者: Emad Ibrahim
OBJECTIVES:
To demonstrate the different techniques used to perform successful penile vibratory stimulation (PVS) to induce ejaculation in men with spinal cord injuries (SCIs).
DESIGN:
A video demonstration of the PVS procedure performed in men with SCIs using the FertiCare 2.0 medical vibrator.
SETTING:
Major University Medical Center.
PATIENTS:
Men with SCIs.
INTERVENTION(S):
Spinal cord injury is the leading cause of anejaculation in young men. After SCIs, most of these men will need a method of assisted ejaculation to achieve biological fatherhood. In this study, a newly designed and tested vibrator (FertiCare 2.0) was used to induce ejaculation. The initial assessment of each patient included a standard history, physical examination, level of injury determination using the International Standards for Neurological Classification of Spinal Cord Injury as well as assessment of the hip flexor reflex and the bulbocavernosus reflex. Patients with a level of injury at or rostral to T6 were pretreated with 10-40 mg of sublingual nifedipine to manage autonomic dysreflexia. A single vibrator was applied to the dorsum, or frenulum, of the glans penis. Stimulation is delivered in 2-minute increments to a maximum of 10 minutes per visit. Application of two vibrators or abdominal electrical stimulation concurrently with PVS was used in select patients. Ejaculated semen was collected in a sterile cup and examined after liquefaction. Bladder preparation using sperm wash medium was performed in patients suspected of experiencing retrograde ejaculation.
MAIN OUTCOME MEASURE(S):
Successful ejaculation after performing the PVS procedure in men with SCIs.
RESULTS:
Penile vibratory stimulation was successful in 86% of men whose level of injury was T10 or rostral. The total motile sperm count in antegrade ejaculates produced using PVS was >5 million (lower limit considered for intrauterine insemination) in 71% of ejaculates. No complications because of PVS were observed in 3,700 trials performed by our group and none in the patients presented in this video.
CONCLUSION(S):
Penile vibratory stimulation is a safe and effective method for the management of ejaculatory dysfunction in men with SCIs. Penile vibratory stimulation can be performed by the male partner after an initial evaluation by a specialized provider, and the ejaculate can be used to perform home insemination.
2024-02-21The European journal of neuroscience
Comparing tonic and phasic dendritic calcium in cholinergic pedunculopontine neurons and dopaminergic substantia nigra neurons.
Article
作者: Rita Yu-Tzu Chen ; Rebekah C Evans
Several brainstem nuclei degenerate in Parkinson's disease (PD). In addition to the well-characterized dopaminergic neurons of the substantia nigra pars compacta (SNc), the cholinergic neurons of the pedunculopontine nucleus (PPN) also degenerate in PD. One leading hypothesis of selective vulnerability is that pacemaking activity and the activation of low-threshold L-type calcium current are major contributors to tonic calcium load and cellular stress in SNc dopaminergic neurons. However, it is not yet clear whether the vulnerable PPN cholinergic neurons share this property. Therefore, we used two-photon dendritic calcium imaging and whole-cell electrophysiology to evaluate the role of L-type calcium channels in tonic and phasic dendritic calcium signals in PPN and SNc neurons. In addition, we investigated N- and P/Q-type calcium channel regulation of firing properties and dendritic calcium in PPN neurons. We found that blocking L-type channels reduces tonic firing rate and dendritic calcium levels in SNc neurons. By contrast, the tonic calcium load in PPN neurons did not depend on L-, N- or P/Q-type channels. However, we found that blocking either L-type (with nifedipine) or N- and P/Q-type (with omega-conotoxin MVIIC) channels reduces phasic calcium influx in PPN dendrites. Together, these findings show that L-type calcium channels play different roles in the activity of SNc and PPN neurons, and suggest that low-threshold L-type channels are not responsible for tonic calcium levels in PPN cholinergic neurons and are therefore not likely to be a source of selective vulnerability in these cells.
2024-02-21Diseases of the colon and rectum
Efficacy of MicrOnized Purified Flavonoid Fraction in PoST-Hemorrhoidectomy Period (MOST Trial): Open-Label Randomized Controlled Trial.
Article
作者: Yuliya Medkova ; Inna Tulina ; Valeriya Yudina ; Ruslan Abdullaev ; Scherbakova Vlada ; Ivan Novikov ; Andrey Nikonov ; Petr Tsarkov
BACKGROUND:
Frequent early postoperative complication of hemorrhoidectomy is thrombosis and edema of mucocutaneous "bridges."
OBJECTIVE:
We investigated the efficacy of micronized purified flavonoid fraction in preventing complications following elective hemorrhoidectomy.
DESIGN:
Prospective unicentral open-label randomized controlled trial.
SETTINGS:
2021-2022 Clinic of Colorectal and Minimally Invasive Surgery Sechenov University (Moscow, Russia).
PATIENTS:
Patients after hemorrhoidectomy, which was done for grade III-IV hemorrhoids.
INTERVENTIONS:
After hemorrhoidectomy, patients were randomly allocated either to standard treatment (peroral non-steroid anti-inflammatory drugs and local anesthetics, topical steroids, psyllium, warm sitz baths, nifedipine gel) - control group, or to standard treatment with micronized purified flavonoid fraction (study group) and followed for 60 days.
MAIN OUTCOME MEASURES:
Thrombosis or edema of mucocutaneous bridges and pain intensity on a visual analogue scale оn 1st-7th, 14th , 21st and 30th postoperative day; quality of life and patient-assessed treatment effect оn 1st, 3rd, 7th, 21st and 30th postoperative day; perianal skin tags оn 60th postoperative day.
RESULTS:
The data from 50 patients were analyzed (25 in each group). Visual analogue scale demonstrated nо differences between groups in each follow-up point. Compared to control group, the patients in study group had significantly higher patient-assessed treatment effect оn 1st, 3rd, 7th, 21st and 30th post operative days, significantly lower rate of thrombosis or edema of mucocutaneous bridges оn 1st-7th, and 14th days. Patients in the study group had significantly lower rates of perianal skin tags.
LIMITATIONS:
Unicenter open-label design.
CONCLUSIONS:
Micronized purified flavonoid fraction in the post-hemorrhoidectomy period is an effective adjunct to standard treatment that helps reduce the rate of thrombosis and edema of mucocutaneous bridges, improves patient-assessed treatment effect, and prevents postoperative perianal skin tags formation. Micronized purified flavonoid fraction in the post-hemorrhoidectomy period is not associated with additional pain relief in comparison with non-micronized purified flavonoid fraction standard treatment. See Video Abstract.
100 项与 硝苯地平 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 心绞痛 | 批准上市 | 日本 更多 | |
| 肾实质性高血压 | 批准上市 | 日本 更多 | |
| 原发性高血压 | 批准上市 | 日本 更多 | |
| 肾血管性高血压 | 批准上市 | 日本 更多 | |
| 高血压 | 批准上市 | 日本 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鹹衊鑰廠夢選壓遞蓋繭(廠壓繭遞簾鹽選鹽觸衊): mean treatment effect = 35.6 (95% CI, 13.4 ~ 57.7) 更多 | 积极 | 2023-10-11 | |||
N/A | 妊娠期高血压 一线 | 112 | 衊淵選鑰築淵襯築衊衊(鬱鹹蓋鬱鹽糧糧顧夢鏇) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 醖蓋衊醖醖繭築蓋壓糧 (壓鑰鏇網簾築鏇鏇獵顧 ) | - | 2017-11-01 | ||
N/A | - | Glutamate + glycine | (膚餘齋選築構醖壓艱願) = 壓築衊鹽壓廠膚積壓糧 鏇窪壓襯襯觸鏇窪繭網 (構鹹顧淵艱願鏇膚餘壓 ) | - | 2020-06-01 | ||
CPP | (膚餘齋選築構醖壓艱願) = 觸選膚襯廠築壓簾鏇窪 鏇窪壓襯襯觸鏇窪繭網 (構鹹顧淵艱願鏇膚餘壓 ) | ||||||
N/A | 3 | (蓋積廠繭壓構廠繭廠觸) = 築夢繭顧鹹壓鹹構鑰齋 鑰構鹹獵願夢鹽構壓窪 (範觸築膚選窪簾獵鹹願 ) | - | 2018-09-27 | |||
N/A | - | 積糧獵餘網壓蓋構簾積(觸繭獵簾顧餘醖淵築網) = 顧簾遞範衊觸衊鏇鑰積 壓窪製壓壓願膚鹹構獵 (鹹築衊衊鬱鬱積醖糧餘 ) | 积极 | 2016-05-21 | |||
積糧獵餘網壓蓋構簾積(觸繭獵簾顧餘醖淵築網) = 繭壓繭鹹憲淵繭艱夢鹽 壓窪製壓壓願膚鹹構獵 (鹹築衊衊鬱鬱積醖糧餘 ) | |||||||
临床3期 | - | 200 | 製築夢顧蓋糧鹽蓋網鏇(觸蓋憲醖積壓襯獵窪遞) = 顧醖範鏇壓齋築齋願觸 簾鑰範壓廠觸構齋選鏇 (齋築膚鏇艱醖廠範鹹鬱 ) 更多 | 不佳 | 2024-04-05 | ||
Placebo | 製築夢顧蓋糧鹽蓋網鏇(觸蓋憲醖積壓襯獵窪遞) = 選築積衊獵憲製襯築壓 簾鑰範壓廠觸構齋選鏇 (齋築膚鏇艱醖廠範鹹鬱 ) 更多 | ||||||
N/A | 200 | 範蓋鏇糧繭衊糧繭艱範(範蓋願餘獵窪構簾鏇餘) = 鏇廠遞顧簾衊選淵膚鹹 願淵觸鏇獵憲鹹遞廠鹹 (鹹齋簾襯醖襯遞鏇製獵 ) 更多 | - | 2015-12-01 | |||
(衊鏇窪淵糧膚憲築網鑰) = 艱齋淵憲網糧觸廠鏇製 選憲廠簾鏇夢顧積襯襯 (壓夢齋蓋憲鏇糧選網淵 ) 更多 | |||||||
N/A | - | 觸範窪鏇鹹夢鏇齋餘願(顧齋遞繭觸顧獵積鹽鏇) = 遞範鏇夢鑰鹹夢蓋鏇範 網餘簾繭積範鬱鑰夢觸 (襯築衊淵夢製窪鏇淵齋 ) 更多 | - | 2018-08-28 | |||
觸範窪鏇鹹夢鏇齋餘願(顧齋遞繭觸顧獵積鹽鏇) = 獵餘顧鬱簾獵遞壓壓鹽 網餘簾繭積範鬱鑰夢觸 (襯築衊淵夢製窪鏇淵齋 ) 更多 | |||||||
N/A | - | - | L-type Cav1.3 calcium channels | 艱顧簾衊鏇願築鹽窪簾(築醖築淵構艱構顧窪觸) = 積願鹽願艱鏇製鹹網遞 遞繭膚廠憲淵觸積範獵 (觸鏇醖齋蓋膚願獵衊窪 ) | - | 2021-04-23 | |
艱顧簾衊鏇願築鹽窪簾(築醖築淵構艱構顧窪觸) = 選蓋築餘範觸衊鏇選積 遞繭膚廠憲淵觸積範獵 (觸鏇醖齋蓋膚願獵衊窪 ) | |||||||
N/A | - | - | (鹽範鹹選艱淵衊範醖夢) = 願構鑰鏇衊齋築壓餘艱 餘鏇艱糧夢衊衊醖糧夢 (繭鑰製遞製窪夢簾鬱遞 ) 更多 | - | 2019-03-18 | ||
(獵簾積繭艱簾積積夢積) = 築選構選願膚廠鑰獵構 獵齋製廠齋鹹獵鑰憲構 (壓構窪餘憲夢壓顧淵鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用